Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMTX705 in Advanced/Metastatic Pancreatic Adenocarcinoma
NCT07377045Phase 1Recruiting
- Sponsor
- Oncomatryx
- Start
- Oct 2025
- Primary completion
- Mar 2029
- Modality
- Antibody-Drug Conjugates (ADCs), Immunotoxins, Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of OMTX705 in pancreatic adenocarcinoma (PDAC) (5 arms), sponsored by Oncomatryx. Primary endpoints: Dose Limiting Toxicities, Treatment Emergent Adverse Events and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
OMTX705
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07377045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377045.